Related Experiment Video

Updated: Jan 29, 2026

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay
12:49

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay

Published on: May 25, 2015

10.5K

Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias

Constantine E Kosmas1, Loukianos S Rallidis1, Ioannis Hoursalas2

  • 12nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece.

International Journal of Molecular Sciences
|January 28, 2026
PubMed

Insights

Targeting Angiopoietin protein-like 3 (ANGPTL3) offers a novel strategy for managing dyslipidemia and cardiovascular disease (CVD). Inhibiting ANGPTL3 effectively lowers LDL-cholesterol, independent of LDL receptor function, through various therapeutic modalities.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death, necessitating effective dyslipidemia management.
  • Understanding lipoprotein metabolism is key to developing innovative CVD therapies.
  • Angiopoietin protein-like 3 (ANGPTL3) is a critical regulator of lipoprotein metabolism.

Purpose of the Study:

  • To review the role of ANGPTL3 in lipoprotein metabolism.
  • To discuss therapeutic strategies targeting ANGPTL3 for dyslipidemia.
  • To evaluate clinical trial data for ANGPTL3 inhibition therapies.

Main Methods:

  • Review of ANGPTL3 structure and function.
  • Analysis of therapeutic approaches: monoclonal antibodies, antisense oligonucleotides, small interfering RNAs, and gene editing.
  • Examination of clinical trial results for Evinacumab and nucleic acid therapeutics.

Main Results:

  • ANGPTL3 inhibition lowers LDL-cholesterol independently of LDL receptor function.
  • Evinacumab (monoclonal antibody) shows clinical efficacy and safety.
  • Nucleic acid therapeutics demonstrate effectiveness in reducing ANGPTL3 protein production.
  • Gene editing approaches like CRISPR/Cas show future therapeutic potential.

Conclusions:

  • ANGPTL3 inhibition represents a promising therapeutic avenue for cardiovascular disease.
  • Diverse strategies, including antibodies, nucleic acids, and gene editing, are being explored for ANGPTL3 targeting.
  • Further research and clinical trials are essential to optimize ANGPTL3-targeted therapies for cardiovascular risk reduction.

Keywords:
ANGPTL3 inhibitorsCRISPR-Cas systemsangiopoietin-like 3antisense oligonucleotides (ASOs)dyslipidemiaevinacumabgene editingsmall interfering RNAs (siRNAs)solbinsiranzodasiran

More Related Videos

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management06:43

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Published on: November 21, 2017

25.0K
Scalable Fluidic Injector Arrays for Viral Targeting of Intact 3-D Brain Circuits13:36

Scalable Fluidic Injector Arrays for Viral Targeting of Intact 3-D Brain Circuits

Published on: January 21, 2010

14.9K

Related Concept Videos

ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH301:11

ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

All ortho–para directors, excluding halogens, are activating groups. These groups donate electrons to the ring, making the ring carbons electron-rich. Consequently, the reactivity of the aromatic ring towards electrophilic substitution increases. For instance, the nitration of anisole is about 10,000 times faster than the nitration of benzene. The electron-donating effect of the methoxy group in anisole activates the ortho and para positions on the ring and stabilizes the corresponding...
7.4K
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
425
Impression Management Techniques I: Managing Appearances01:29

Impression Management Techniques I: Managing Appearances

Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
214
Managing Impressions01:19

Managing Impressions

Impression management encompasses individuals' deliberate efforts to shape how others perceive them during social interactions. This behavior is often employed to conform to social norms, secure approval, or pursue specific goals. While it involves selective self-presentation, it is not necessarily deceptive; individuals frequently present authentic aspects of themselves that align with situational demands.Common strategies include:Ingratiation: where individuals use flattery or agreeableness...
169
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
612
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
520